Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

Use of the product showed positive changes in the skin’s hydration, lipid content, transepidermal water loss, and erythema.

CBD and CBG Ointment Improved Skin in Patients with Atopic Dermatitis

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

A study shows active educational interventions improve melanoma detection rates and rule application, with lasting effects over time.

Active Education Outperforms Passive Approaches in Melanoma Detection by Non-Medical Individuals

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Researchers behind a recent review shared expert insights, treatment guidelines, and differential diagnosis techniques for pediatric rosacea.

An Up-to-Date Review of Rosacea in Childhood and Adolescence 

When compared to a non-active product, the formula improved texture, reduced erythema, and strengthened the skin barrier.

Novel Moisturizing Formulation is Effective for Repairing Skin After Microneedling

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

LaShell Robinson is the executive director and global head for global feasibility and trial equity at Takeda Pharmaceuticals. 

Robinson shared insights into how the company is working to fight clinical research disparities.

LaShell Robinson on Takeda’s Initiative to Improve Research Diversity

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Hyperhidrosis affects approximately 385 million people globally, surpassing the prevalence of other dermatologic conditions like psoriasis. It is notably more common in younger populations, with 8.8% of individuals aged 18 to 39 experiencing the condition. Comparatively, hyperhidrosis is more prevalent than natural red or blond hair, which affects 1% and 2% of the population, respectively. Despite its prevalence, 27% of those with hyperhidrosis remain undiagnosed. The article encourages engagement during Hyperhidrosis Awareness Month to share insights and research on the condition.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

Polls 

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

Dermatology Times spoke with Paul Yamauchi, MD, PhD, a lead investigator on the trial.

New Research Confirms Effective Therapy for Nail Psoriasis

, Paul Yamauchi, MD, PhD, a board-certified dermatologist at the Dermatology Institute and Skincare Center in Santa Monica, California, spoke about his involvement in a clinical trial evaluating the efficacy of tildrakizumab, a biologic therapy, in treating moderate to severe nail psoriasis. In addition to his private practice, Yamauchi has conducted over 200 clinical trials through the Clinical Science Institute, a research center he founded.

During the interview, Yamauchi emphasized the importance of specific trials for these subgroups of psoriasis patients, stating, "Placebo-controlled trials provide more accurate and reliable data than post hoc analysis."

The study focused on 2 primary endpoints measured at week 28, given that nails grow slowly and require extended observation periods for assessment. The first endpoint was the modified Nail Psoriasis Severity Index (NAPSI) score, which evaluates characteristics such as pitting, nail separation, thickening, and discoloration. According to Yamauchi, a 75% improvement in the modified NAPSI score was observed in 25% of subjects receiving tildrakizumab, compared to only 4.2% in the placebo group The second endpoint was the Visual Index for Severity of Nail Psoriasis (VISNAP), a 5-point scale developed by Sun Pharmaceuticals. Yamauchi explained, "For the VISNAP response at week 28, 29% of subjects attained clear or almost clear nails, compared to a placebo rate of 4.2%." This significant separation between the treatment and placebo groups suggests that tildrakizumab is effective for treating nail psoriasis.

Yamauchi previously investigated tildrakizumab for scalp psoriasis, another high-impact area, which also met its primary endpoints. Yamauchi noted that Sun Pharmaceuticals is planning further trials for genital, hand, and foot psoriasis. He mentioned that topical therapies are typically the first-line treatment for nail and scalp psoriasis. However, if topical treatments fail, systemic options such as pills or injections become necessary. He highlighted tildrakizumab’s advantage, stating, "Since it is administered every3 months, it is very convenient for the patient and a safe product, making it a good choice as a first-line systemic agent."

Safety was another crucial aspect discussed in the trial. Tildrakizumab demonstrated a favorable safety profile, with the most common adverse effects being minor infections. The drug had no significant warnings beyond this, reinforcing its potential as a viable treatment option.

Yamauchi's insights underscore the promising role of tildrakizumab in treating nail psoriasis. The placebo-controlled trial's strong efficacy results, combined with the drug’s safety and convenience, make it a compelling option for patients who do not respond adequately to topical therapies. Additionally, ongoing research may expand its indications to other challenging psoriasis-affected areas, providing further therapeutic options for patients.

Tildrakizumab, a biologic therapy, shows promise in treating moderate to severe nail psoriasis, as demonstrated in a clinical trial led by Dr. Paul Yamauchi. The trial's primary endpoints, the modified Nail Psoriasis Severity Index (NAPSI) and the Visual Index for Severity of Nail Psoriasis (VISNAP), revealed significant improvements in patients receiving tildrakizumab compared to placebo. The drug's favorable safety profile and convenient administration every three months enhance its appeal as a first-line systemic treatment. Further research may extend its use to other psoriasis-affected areas, broadening therapeutic options.

Nail psoriasis affects 50% of plaque psoriasis patients, making effective treatments crucial.


Tomassian noted unrealistic beauty standards fueled by social media filters and edited images have led to distorted expectations.

Social Media “Hacks”: DIY Sunscreen, Slugging, and More With Chris Tomassian, MD

Chris Tomassian, MD, a board-certified dermatologist and founder of The Dermatology Collective, is passionate about debunking skincare misinformation and educating the public via social media. During an interview with 

, he said one of the most concerning trends he has seen is the rise of DIY sunscreen, where individuals attempt to create their own sun protection at home. He explains that many people mistakenly believe sunscreen is harmful or even cancerous, leading them to seek homemade alternatives. However, as he warns, “People are taking matters into their own hands, and they're like, ‘I could bake bread, so I could bake a sunscreen in my house.’” He emphasizes that commercial sunscreens go through rigorous testing to ensure they effectively block UV rays, whereas homemade versions lack the necessary stabilizers and preservatives, putting users at risk for sunburns and skin cancer.

Tomassian also addresses the broader issue of misinformation in dermatology, particularly on social media platforms like TikTok. He notes that many misleading skin care products gain traction through viral marketing and fake reviews, often promoting unproven claims without scientific backing. This has made it increasingly difficult for patients to differentiate between legitimate, research-backed treatments and trendy but ineffective solutions. “There’s no face behind the product, but it will go viral,” he explains, highlighting how the lack of regulation allows misinformation to spread unchecked.

Another major challenge he faces is the skepticism many patients now have toward established medical advice. While he acknowledges that patient advocacy and research are beneficial, he also finds himself frequently correcting misconceptions, such as the belief that isotretinoin is dangerous despite decades of clinical evidence supporting its effectiveness for severe acne. Additionally, social media has contributed to unrealistic beauty standards through filters and edited images, leading some patients to expect impossible cosmetic results. “They probably had surgery, they had all these things done,” he says, emphasizing that one syringe of filler cannot achieve the dramatic transformations often seen online.

Despite the challenges, Tomassian sees positives in social media, particularly when used to educate and inform. He praises trends like skin minimalism and skin cycling, which encourage a more thoughtful approach to skincare. Looking forward, he plans to expand his practice with a second location in Los Angeles by 2026 and is also exploring new ways to reach audiences. Through these efforts, he continues to push his mission of providing expert dermatological care while combatting misinformation in the ever-evolving world of skincare.

Chris Tomassian, MD, a dermatologist, is committed to debunking skincare misinformation, particularly the rise of DIY sunscreen, which lacks the rigorous testing of commercial products. He highlights the challenges posed by social media, where viral marketing and fake reviews spread unproven skincare claims, complicating patient discernment. Tomassian also addresses skepticism towards established medical advice and the unrealistic beauty standards perpetuated online. Despite these issues, he sees social media's potential for education and plans to expand his practice while continuing to combat misinformation in dermatology.

By leveraging the innovative biomarker panels, clinicians can now offer more personalized and effective treatment options for psoriasis and AD.

New Biomarker Test Revolutionizes Inflammatory Skin Disease Diagnosis

William Damsky, MD, PhD, an assistant professor of dermatology at Yale School of Medicine, is dedicated to advancing the understanding and treatment of inflammatory skin diseases. As both a practicing dermatologist and a dermatopathologist, Damsky recognizes the significant "practice gap between what's possible in the research laboratory" and what is currently available in clinical settings. This gap, he notes, is due to challenges such as specimen acquisition, processing expertise, turnaround time, and other logistical barriers. His research aims to bridge this gap by developing molecular diagnostics that can seamlessly integrate into dermatological practice.

Atopic dermatitis and psoriasis are 2 of the most common inflammatory skin diseases, yet they present with significant heterogeneity. "One patient with atopic dermatitis may not be exactly clinically or histologically or immunologically identical to the next," Damsky explains. This variability makes treatment decisions complex, as many FDA-approved therapies have distinct mechanisms of action, but there is little guidance on selecting the best medication for individual patients.

To address this, Damsky and his team examined approximately 100 biomarkers, validating 10 before ultimately selecting4 that proved most effective. Their goal was to determine which molecular markers could best distinguish inflammatory skin diseases and predict treatment responses. They explored various laboratory techniques, ultimately settling on in situ hybridization over immunohistochemistry due to its superior ability to detect cytokines, which are critical to disease pathogenesis and targeted by many modern therapies.

A major advantage of Damsky' approach is that it requires no additional effort from clinicians or pathology labs. "The clinician doesn't need to do anything different. They just do a biopsy, as they always would," he explains. The biopsy can be a new or existing sample, allowing retrospective molecular classification of patients. By running the stains overnight using a standardized protocol, results are available the next morning, facilitating rapid and informed treatment decisions.

Damsky envisions a future where molecular diagnostics become routine in dermatology, enabling precise disease classification and more effective use of targeted therapies. This approach could be particularly transformative for rare or severe skin conditions that currently lack FDA-approved treatments. His collaboration with Molecular Instruments has been instrumental in developing RNA probes that preserve tissue morphology and produce clear signals, further enhancing the utility of this technique.

Inflammatory skin disease research is undergoing a "translational revolution," yet clinical practice still lags behind laboratory discoveries. By integrating molecular diagnostics into standard dermatological workflows, Damsky and his team hope to close this gap, ultimately improving patient outcomes and expanding treatment options for a wide range of skin diseases.

William Damsky, MD, PhD, is focused on bridging the gap between dermatological research and clinical practice by developing molecular diagnostics for inflammatory skin diseases. His work addresses the heterogeneity in conditions like atopic dermatitis and psoriasis, which complicates treatment decisions. By identifying and validating biomarkers, Damsky aims to enhance disease classification and predict treatment responses. His approach integrates seamlessly into existing clinical workflows, requiring no additional effort from clinicians. This advancement could revolutionize dermatology, particularly for rare or severe conditions lacking FDA-approved treatments.

Ahead of the annual meeting, Dermatology Times spoke with Draelos about why she looks forward to the meeting each year.

Zoe Diana Draelos, MD: Gearing Up for AAD

This weekend, the dermatology community kicks off the biggest conference of the year in Orlando, Florida, with the American Academy of Dermatology (AAD) annual meeting. Clinicians from around the globe will meet to share pearls, discuss upcoming therapeutics, and review late-breaking data. Among this cohort of attendees and presenters are a number of 

 Editorial Advisory Board (EAB) members, including 

Andrew F. Alexis, MD, MPH, FAAD, Pearl Grimes, MD, FAAD, 

Read our full breakdown of EAB member sessions at this years’ AAD meeting 

Joining her fellow EAB members is Zoe Diana Draelos, MD, FAAD, consulting professor at Duke University School of Medicine and founder of Dermatology Consulting Services, PLLC. Draelos will be involved in 3 sessions at the meeting: The Future of Cosmetic Dermatology, Medical and Surgical Management of Nail Disorders, and The Science of Cosmeceuticals and Nutraceuticals.

spoke with Draelos who shared her excitement for the conference, its sessions, and its speakers. “It's just a great time to make new friends, meet other dermatologists, see where they are in their practice,” she said. “I think going to the AAD, for me, is very invigorating, very rejuvenating, and it’s just fun to see where everybody’s been for the past year.” She shared that this is also a good opportunity to mentor younger clinicians, as the meeting is quite comprehensive.

Draelos was particularly excited about her presentation on nutraceuticals: “I think that’s always a fun session, because we really drill down to, ‘Where’s the science? Where is anti-aging medicine going? Nutritionally, what do you eat to help?’...it’s such a future session, looking at where are we now and what can we do to be sure that we all have quality skin for an entire lifetime.”

 staff will be onsite at the Orange County Convention Center for AAD 2025. Subscribe to our 

 for the latest in expert insights, exclusive interviews, and late-breaking data.

 for more insights from Draelos, including more interviews with 

LaShell Robinson

Articles

Latest Updated Articles